OTCMKTS:PVTTF Pivotal Therapeutics (PVTTF) Stock Price, News & Analysis → Central Bank Gold Heist In Progress (From Colonial Metals) (Ad) Free PVTTF Stock Alerts $0.0018 0.00 (0.00%) (As of 05/12/2023) Add Compare Share Share Today's Range$0.0018▼$0.001850-Day Range N/A52-Week Range$0.0018▼$0.0018VolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisHeadlinesStock AnalysisHeadlines Get Pivotal Therapeutics alerts: Email Address Ad Colonial MetalsCentral Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. About Pivotal Therapeutics Stock (OTCMKTS:PVTTF)Pivotal Therapeutics Inc., a specialty pharmaceutical company, focuses on the treatment of cardiovascular diseases and overall health. Its lead product, VASCAZEN, is a prescription only medical food formulated for clinical dietary management of cardiovascular disease in patients with documented coronary heart disease and who are deficient in blood Omega-3 fatty acids, eicosapentaenoic acid, and docosahexanenoic acid levels. The company also offers OMAZEN for the maintenance of good health through elevating Omega-3 fatty acid levels. In addition, the company develops Benefishial product line for overall health, cardiovascular health, prenatal health, toddler's health, child's health, and pet's health. Further, it is developing PVT-100 indicated for the stabilization of vulnerable plaque in patients undergoing carotid endarterectomy. Pivotal Therapeutics Inc. sells VASCAZEN in the United States and OMAZEN in Canada. The company is headquartered in Woodbridge, Canada.Read More PVTTF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PVTTF Stock News HeadlinesFebruary 28, 2024 | markets.businessinsider.comBuy Rating for Viridian Therapeutics Backed by Strong Financials and Promising Drug CandidateFebruary 24, 2024 | businessinsider.comPivotal, the flying-car company backed by Google cofounder Larry Page, lays off 10% of staffMarch 18, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.February 22, 2024 | markets.businessinsider.comPivotal Delivers Four BlackFly light eVTOLs for U.S. Air Force evaluation; Contracted for Eight AircraftFebruary 22, 2024 | tmcnet.comPivotal Commware Promotes FWA Without Limits at 2024 Mobile World Congress BarcelonaFebruary 9, 2024 | msn.comDCC Animal Hospital onboards Dr. Prabhakaran Palanichamy as Senior Veterinary ExpertFebruary 6, 2024 | msn.comVertex's (VRTX) Q4 Earnings and Sales Surpass EstimatesFebruary 5, 2024 | finance.yahoo.comGlobal Downstream Processing Market to Surpass 83.47 Billion by 2030 Driven by Rising Demand for BiopharmaceuticalsMarch 18, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.January 30, 2024 | msn.comVertex non-opioid painkiller shows positive results in critical late-stage trial on acute painDecember 18, 2023 | businesswire.comViridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended ...December 18, 2023 | finance.yahoo.comPivotal Life Sciences Announces the Closing of $389M for Pivotal bioVenture Partners Fund IIDecember 12, 2023 | finance.yahoo.comGlobal Semiconductor Industry Outlook 2024December 12, 2023 | finance.yahoo.comNuclear Medicine Market Valuation to Soar at 11.5% by 2030, Global Revenue to Exceed US$11 Bn: Fairfield Market ResearchNovember 21, 2023 | markets.businessinsider.comPivotal Appoints Cyrus Sigari to its Board of DirectorsOctober 25, 2023 | uk.finance.yahoo.comGlobal Neuromuscular Disease Therapeutics Market to Surge by $6.51 Billion by 2027, Driven by Novel Approvals and Screening TestsOctober 25, 2023 | msn.comJenaValve Trilogy heart valve meets primary endpoints in pivotal trialOctober 24, 2023 | markets.businessinsider.comJenaValve Announces Late-Breaking Data from the ALIGN-AR Pivotal Trial Meeting Safety and Efficacy EndpointsOctober 19, 2023 | venturebeat.comProtembis Announces FDA Approval of its Pivotal Investigational Device Exemption (IDE) StudySeptember 30, 2023 | usnews.comVideo Provides First Clear Views of WWII Aircraft Carriers Lost in the Pivotal Battle of MidwaySeptember 4, 2023 | usnews.comIn the Pivotal South Carolina Primary, Republican Candidates Search for a Path Against Donald TrumpSeptember 4, 2023 | msn.comProtagonist Therapeutics: Evaluating Rusfertide's Potential For PVAugust 15, 2023 | msn.comSVB Securities Maintains Viracta Therapeutics (VIRX) Outperform RecommendationAugust 14, 2023 | markets.businessinsider.comViracta Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 9, 2023 | msn.comHow Does Pivotal Response Training (PRT) for Children With Autism Work?August 7, 2023 | markets.businessinsider.comPivotal Research Sticks to Their Buy Rating for Liberty Broadband (LBRDK)July 25, 2023 | finance.yahoo.comSERD Therapeutics Market Recording a Promising CAGR of 17.5% from 2023-2031 | Reveals InsightAce StuydSee More Headlines Receive PVTTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pivotal Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:PVTTF CUSIPN/A CIKN/A Webwww.pivotaltherapeutics.us Phone(289) 597-7970FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta-0.66 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMs. Rachelle MacSweeneyCo-Founder, CEO, President & DirectorMr. George Jackowski (Age 73)Co-Founder, Chief Scientific Officer & Director Comp: $266.07kKey CompetitorsAbliva AB (publ)OTCMKTS:NEVPFAcusphereOTCMKTS:ACUSADC TherapeuticsNYSE:ADCTAddex TherapeuticsOTCMKTS:ADDXFAeolus PharmaceuticalsOTCMKTS:AOLSView All Competitors PVTTF Stock Analysis - Frequently Asked Questions How have PVTTF shares performed in 2024? Pivotal Therapeutics' stock was trading at $0.0018 on January 1st, 2024. Since then, PVTTF stock has increased by 0.0% and is now trading at $0.0018. View the best growth stocks for 2024 here. How do I buy shares of Pivotal Therapeutics? Shares of PVTTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:PVTTF) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe world’s greatest investmentPorter & CompanyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingBill Gates Bets on $15 Trillion BonanzaWeiss RatingsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pivotal Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.